Biotechnology company Glycosyn sued German company Jennewein, accusing it of infringing U.S. Patent 9,453,230 by manufacture and sale and/or importation into the United States of human milk oligosaccharide products produced by engineered E. coli bacterial strain. These products, which are believed to treat or prevent infections in infants, are intended to be added to formula strains to provide their benefits to infants not being breast-fed. Jennewein sought and obtained FDA approval to bring its products, sold under the name 201cMum 2019s Sweet Secret, 201d into the country in November 2015, while the 2018230 patent was still pending.
By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
SHARE THIS POST
